

Committee on Energy and Commerce
U.S. House of Representatives
 Witness Disclosure Requirement - "Truth in Testimony"
 Required by House Rule XI, Clause 2(g)(5)

1. Your Name: Patrick M. Beardsley, Ph.D.		
2. Your Title: Professor, Pharmacology and Toxicology		
3. The Entity(ies) You are Representing: Self; selected by American Society for Pharmacology and Experimental Therapeutics		
4. Are you testifying on behalf of the Federal, or a State or local government entity?	Yes	No x
<p>Please list any Federal grants or contracts, or contracts or payments originating with a foreign government, that you or the entity(ies) you represent have received on or after January 1, 2015. Only grants, contracts, or payments related to the subject matter of the hearing must be listed.</p> <p>1. Beardsley, P. M., (PI) (2017-2022). Preclinical medications discovery and abuse liability testing for the National Institute on Drug Abuse. \$4,318,971. \$7,607,514 (Ultimate Contract Value (Base Period, Option Periods, and Option Quantities), National Institute on Drug Abuse.</p> <p>2. Beardsley, P. M. (PI) (2017). Analgesia studies: Solicitation number: D-17-OD-0092, Drug Enforcement Agency. \$149,040.</p> <p>3. Beardsley, P. M., (PI) (2014). Medication discovery using rat models of relapse. \$2,954,759. \$4,496,997 (Ultimate Contract Value (Base Period, Option Periods, and Option Quantities), National Institute on Drug Abuse.</p>		
1. Please attach your curriculum vitae to your completed disclosure form.		

Signature:  Date: 20180228

CURRICULUM VITAE

PATRICK M. BEARDSLEY, Ph.D.

Virginia Commonwealth University

*Department of Pharmacology & Toxicology,
Institute for Drug and Alcohol Studies
&*

Center for Biomarker Research and Personalized Medicine

410 N. 12th St., Smith Bld. #756
Box 980613
Richmond, VA 23298-0613



Employment

- 2003-present *Professor of Pharmacology & Toxicology, Virginia Commonwealth University, Medical College of Virginia Campus, Richmond, Virginia.*
- 2015-present *Adjunct Professor, Center for Biomarker Research and Precision Medicine, School of Pharmacy, Virginia Commonwealth University, Medical College of Virginia Campus, Richmond, Virginia.*
- 2008-present *Special Government Employee (SGE), Food & Drug Administration, Washington, DC.*
- 2004-present *Affiliate Research Professor of Psychology, Virginia Commonwealth University, Richmond, Virginia*
- 1993-2003 *Associate Professor of Pharmacology & Toxicology, Medical College of Virginia, Richmond, Virginia.*
- 1994-2004 *Affiliate Research Associate Professor of Psychology, Virginia Commonwealth University, Richmond, Virginia*
- 1992-1993 *Project Leader - Drug Discovery, Glaxo S.p.A., Ricerche, Verona, Italy.*
- 1992-1993 *Affiliate Associate Professor of Pharmacology & Toxicology, Medical College of Virginia, Richmond, Virginia.*

- 1988-1992 *Senior Research Scientist, Department of Central Nervous System Diseases Research, G.D. Searle & Co., Skokie, Illinois.*
- 1987-1988 *Research Assistant Professor of Pharmacology & Toxicology, Medical College of Virginia, Richmond, Virginia.*
- 1985-1987 *Research Instructor of Pharmacology & Toxicology, Medical College of Virginia, Richmond, Virginia.*
- 1985-1986 *Consultant, Veterans Administration Hospital, Richmond, Virginia.*
- 1983-1985 *Postdoctoral Training Fellow, Medical College of Virginia, Department of Pharmacology - CNS Division, Richmond, Virginia.*
- 1982-1983 *Postdoctoral Research Fellow, Addiction Research Foundation, Toronto, Ontario, Canada.*

Education

- 1995-1996 Medical College of Virginia, Richmond, Virginia.
Graduate studies in Clinical Trials Design and Statistics
- 1990-1991 MBA Program Studies, Roosevelt University, Chicago, Illinois
- 1977-1982 **Ph.D.** University of Minnesota, Minneapolis, Minnesota. Awarded date of Ph.D.: 1982.
- 1975-1976 Florida State University, Tallahassee, Florida.
Graduate studies in statistics, theories of learning and applied behavioral analysis.
- 1971-1974 **B.A. (*Summa cum Laude*)**, University of Minnesota, Minneapolis, Minnesota.
- 1970-1971 Marquette University, Milwaukee, Wisconsin. Course work in journalism and psychology.
- 1966-1970 **High School (*Summa Cum Laude*)**, St. Thomas Military Academy, Mendota Heights, Minnesota.

Awards, Honors, Special Service & Society Affiliations

- 2016 ***FDA Expert Advisory Committee***, Anesthetic and Analgesic Drug Products Advisory Committee and Drug Safety Advisory Committee
- 2016- ***Scientific Advisory Board, "Experimental Design Accelerator"***, National Institute on Drug Abuse
- 2016 ***Expert Advisor, UNODC-WHO Expert Consultation on New Psychoactive Substances***, Geneva, Switzerland.
- 2016 ***Invited Co-chair, Plenary Symposium, Behavior, Biology, and Chemistry: Translational Research in Addiction***, San Antonio, Texas, U.S.A.
- 2015-2019 ***Standing (voting) Committee Member, Expert Committee on Drug Dependence, World Health Organization***, Geneva, Switzerland
- 2015-2019 ***Elected to the Board of Directors***, College on Problems of Drug Dependence
- 2015, 2016 ***Elected Rapporteur, Expert Committee on Drug Dependence, World Health Organization***, Geneva, Switzerland
- 2014 ***Expert Advisor, UNODC-WHO Expert Consultation on New Psychoactive Substances***, Vienna, Austria.
- 2014 ***Best Medical & Pharmaceutical Textbook of the Year (2013) for Post-Graduate* Studies*** for the book: Vespalov AY, (А.Ю. Беспалова), Zvartau EE, (Э.Э. Звартау), Beardsley PM, (П.Бирдсли), Katz JL, (Дж. Катца) (eds). ***Textbook on Behavioral Pharmacology (Фармакология поведения)***. Pavlov Medical University Press (Издательство СПбГМУ им. И.П. Павлова): St. Petersburg, (Санкт-Петербург) Russia (Россия), 2013.
- 2014 ***Special Advisor, World Health Organization Secretariat, Expert Committee on Drug Dependence*** Geneva, Switzerland
- 2014, 2015, 2016 ***Medical Review Writer, World Health Organization***, Geneva, Switzerland

- 2013 **Keynote Speaker, Winter Conference on Animal Learning and Behavior** Winter Park, CO
- 2013-2018 **Appointment as Chair, Committee on Abuse Liability of Drugs (CALD)**, College on Problems of Drug Dependence
- 2012 **Special Advisor, World Health Organization Secretariat, Expert Committee on Drug Dependence** Hammamet, Tunisia
- 2012 **Scientific Advisory Board** Italian Ministry of University & Research (MIUR)
- 2011- **Fellow**, College on Problems of Drug Dependence, Inc.
- 2011 **School of Medicine Outstanding Teacher Award, Department of Pharmacology & Toxicology** Virginia Commonwealth University
- 2011-2016 **Neuropsychiatric Safety Board** Merck Research Laboratories
- 2010 **FDA Expert Advisory Committee (voting member)**, Anesthetic and Life Support Drugs Advisory Committee (ALSDAC)/ Drug Safety and Risk Management Advisory Committee, Center for Drug Evaluation and Research (Risk Evaluation and Mitigation Strategies (REMS) for Extended-Release and Long-Acting Opioid Analgesics)
- 2009 **FDA Expert Advisory Committee (voting member)**, Gastrointestinal Drugs Advisory Committee, Center for Drug Evaluation and Research
- 2009 **FDA Expert Advisory Committee (voting member)**, Anesthetic and Life Support Drugs Advisory Committee (ALSDAC), Center for Drug Evaluation and Research (Efficacy and Safety of Propoxyphene)
- 2009-2012 **Appointment as Chair, Committee on Abuse Liability of Drugs (CALD)**, College on Problems of Drug Dependence
- 2009 **Appointment, Nominating Committee**, College on Problems of Drug Dependence
- 2008 **Visiting Professor Lecture**, FDA Center for Drug

Evaluation and Research (CDER), Visiting Professor Lecture Series (VPLS) co-sponsored by the Office of the Center Director, Controlled Substance Staff and the Office of Executive Programs

- 2007-2011 ***Elected to the Board of Directors***, College on Problems of Drug Dependence
- 2007 ***Member Selection***, 48th Annual Short Course in Medical and Experimental Mammalian Genetics, Bar Harbor, ME
- 2007-2009 ***Appointment, Committee on Abuse Liability Testing (CALT)***, College on Problems of Drug Dependence
- 2003-2006 ***Appointment, Credentials Committee***, College on Problems of Drug Dependence
- 2004 ***Appointment, Program Committee***, College on Problems of Drug Dependence
- 2001-2003 ***Appointment, Development Committee***, College on Problems of Drug Dependence
- 1999- ***Member***, American Society of Pharmacology and Experimental Therapeutics
- 1999-2004 ***Appointment as Standing & Charter Member, Medication Development Research Subcommittee***, National Institute on Drug Abuse Grant Review Group
- 1999-2004 ***Member, Drug Evaluation Committee (DEC)***
- 1997-1999 ***President of ISGIDAR***, International Study Group Investigating Drugs as Reinforcers
- 1995-1997 ***Secretary of ISGIDAR***, International Study Group Investigating Drugs as Reinforcers
- 1995-1997 ***Appointment, Industrial Relations Committee***, College on Problems of Drug Dependence
- 1993- ***Regular Member***, College on Problems of Drug Dependence, Inc.
- 1993 ***Member***, European Behavioural Pharmacology Society

- 1991 **Awardee** of the **Award for Contributions that are Exceptional (ACE)** by the G. D. Searle & Co.
- 1990 **Member**, Society for Neurosciences
- 1990-1993 **Appointment to the Board of Directors**, Illinois Society for Medical Research
- 1987 **GS-13 Rating, Pharmacologist** U.S. Office of Personnel Management Rating
- 1987 **Awardee of The Young Psychopharmacologist Award for 1987** by the American Psychological Association
- 1986- **Member**, Behavioral Pharmacology Society
- 1986 **Member**, Behavioral Toxicology Society
- 1986 **Member**, Sigma Xi Society
- 1985- **Member**, International Study Group Investigating Drugs as Reinforcers
- 1985 **Member**, Society for the Stimulus Properties of Drugs
- 1984 **Awardee of a Travel Fellowship** by the Committee on Problems of Drug Dependence
- 1984 **Member**, American Association for the Advancement of Science
- 1977-1982 **Awardee** of an **Individual Predoctoral National Research Service Award** by the United States Public Health Service
- 1974 **Phi Beta Kappa**, University of Minnesota

Licensure

Drug Enforcement Administration Schedule I Research License, (RB0378338)

Drug Enforcement Administration Schedule II-V Research License (RB0376156, RB0512601, RB0508436)

Science and Managerial Professional Courses

Genetics of Addiction
The Jackson Laboratory
Bar Harbor, ME 2010

Medical and Experimental Mammalian Genetics
The Jackson Laboratory
Bar Harbor, ME 2007

Basic Managerial Skills for R & D.
London Business School
Glaxo Management School
Verona, Italy 1992

Fundamental Approaches to Disease: Brain Mechanisms in Neuropsychology
The Neurosciences Institute (of the Neurosciences Research Program)
The Rockefeller University
New York, NY 1991

Biopharmaceutics & Bioavailability
University of Wisconsin
School of Pharmacy
Madison, WS 1990

Introduction to the Regulatory Process
University of Wisconsin
School of Pharmacy
Madison, WS 1989

Fundamentals of Biochemistry: Background for Biotechnology
Center for Professional Advancement
Princeton, NJ 1989

Project Management
Coates Freeman Associates
New Ipswich, NH
(given in Chicago, IL, 1989)

Publication Reviewer

Ad hoc reviewer for scientific articles for the journals:

Science
Life Sciences

Psychopharmacology
Biological Psychiatry
Physiology and Behavior
Behavioural Pharmacology
Drug and Alcohol Dependence
European Journal of Pharmacology
European Neuropsychopharmacology
Pharmacology Biochemistry and Behavior
Experimental and Clinical Psychopharmacology
Prog in Neuro-Psychopharm & Biological Psychiatry
Journal of Pharmacology & Experimental Therapeutics
and others

Grant Application Reviewer

- 2015 ***Ad hoc reviewer for The Wellcome Trust***
- 2014 ***NCATS TD Reviewer***, National Center for Advancing Translational Sciences, National Institutes of Health, Discovering New Therapeutic Uses Review Team
- 1999-2004 ***Standing & Charter Member, NIH Medication Development Research Subcommittee***, National Institute on Drug Abuse Grant Review Group
- 2003 ***Ad hoc reviewer for NIDA SEP***, Medications Development Research
- 1999-2001 ***Ad hoc reviewer for the NIDA Small Grant Program***, Virginia Commonwealth University, Richmond, VA.
- 2000 ***Ad hoc reviewer for the NIH***, Minority Institution's Drug Abuse Research Development Program
- 2001 ***Ad hoc reviewer for The Wellcome Trust***

Meetings or Symposia Organized or Chaired, Editorial Responsibilities

International Emergence and Abuse of New Psychotropic Substances (NPS), Their Toxicity and the Current Regulatory Response (workshop co-organizer and co-chair with J. C. Maxwell). *College on Problems of Drug Dependence Meeting*, 2016, Palm Springs, CA.

Glial and Neuroinflammatory Targets for Treating Substance Use Disorders (invited co-chair with S.D. Comer), *Behavior, Biology and Chemistry: Translational Research in Addiction (BBC)*, 2016, San Antonio, TX.

- Rapporteur, World Health Organization. (2015). WHO Expert Committee on Drug Dependence Thirty-seventh Report (WHO Technical Report Series).*
- Abuse Deterrent Formulation Science Meeting: Discussion of the FDA Draft Guidance for Industry: Abuse Deterrent Opioids - Evaluation and Labeling (co-organizer and co-chair), 2013, Rockville, MD*
- Preclinical to clinical evidence that glia and neuroinflammation mediate drug abuse and related pathologies (CPDD symposium co-chair), 2013, San Diego, CA.*
- Winter Conference on Animal Learning and Behavior (member, organizing committee), 2013, Winter Park, CO.*
- Science of Abuse Liability Assessment (co-organizer and co-chair) with the FDA and NIDA, 2011, Washington, DC.*
- Bespalov, A. Y., (А.Ю. Беспалова), Zvartau, E. E., (Э.Э. Звартау), Beardsley, P. M., (П.Бирдсли) and Katz, J. L., (Дж. Катца) (Eds.) (2013). Textbook on Behavioral Pharmacology (Фармакология поведения). Pavlov Medical University Press (Издательство СПбГМУ им. И.П. Павлова), St. Petersburg, (Санкт-Петербург) Russia (Россия).*
- Drug Development Research: Special Issue on Potential Therapeutic Applications of Cannabinoid CB1 Antagonists, (co-Editor), 2009.*
- College on Problems of Drug Dependence Meeting, Session: Cocaine/Opiate Interactions: (co-Chair), 2010, Scottsdale, AZ.*
- Winter Conference on Animal Learning and Behavior, Focus Session: Behavioral Pharmacology, Behavioral Economics and Reinforcement Value (Chair), 2009, Winter Park, CO.*
- Drug Self-administration & Physical Dependence Testing (Workshop co-facilitator), Safety Pharmacology Society Meeting 2006, San Diego, CA.*
- Addressing the Emerging Issues in Safety Pharmacology, Abuse Potential Assessment, Issues & Needs (Workshop Chair and Speaker), 2004, Philadelphia, PA.*
- International Study Group Investigating Drugs as Reinforcers Meeting (Organizer), 1999, Acapulco, Mexico.*
- College on Problems of Drug Dependence Meeting, Session: Agonist Treatment for Cocaine Dependence (co-Chair), 1999, Acapulco, Mexico.*
- International Study Group Investigating Drugs as Reinforcers Meeting, Symposium: Behavioral Selectivity in the Evaluation of Candidate Drug Abuse Medications (co-Organizer, co-Chair), 1999, Acapulco, Mexico.*
- International Study Group Investigating Drugs as Reinforcers Meeting (Organizer), 1998, Scottsdale, Arizona.*

Teaching Experience

1995-2016	Director, Behavioral Pharmacology (PHTX 633), Virginia Commonwealth University, Richmond, Virginia
1995-2008	Director, Pharmacology for Nurse Anesthetists (PHTX 516), Virginia Commonwealth University, Richmond, Virginia.
1993-	Lecturer, Virginia Commonwealth University, Richmond, Virginia.
1983-1988	Lecturer, Virginia Commonwealth University, Richmond, Virginia.
1978-1979	Teaching Assistant, University of Minnesota, Minneapolis, Minnesota.
1976	Teaching Assistant, Florida State University, Tallahassee, Florida.
1973	Proctor, University of Minnesota, Minneapolis, Minnesota.

Grants & Contracts (awarded)

Beardsley, P. M. (PI) and Walentiny, D. (co-I). *Analgesia studies: Solicitation number: D-17-OD-0092. Drug Enforcement Agency*. Total costs: \$149,040. Project Period: (08/01/2017 - 02/1/2018).

Beardsley, P. M., (PI). *Preclinical medications discovery and abuse liability testing for NIDA. National Institute on Drug Abuse*. Total costs: \$4,318,971. Ultimate Contract Value (Base Period, Option Periods, and Option Quantities): \$7,607,514. Project Period: (02/22/17 to 02/21/22).

Beardsley, P. M., (PI). *Medication discovery using rat models of relapse. National Institute on Drug Abuse*. Total costs: \$4,496,997. Project Period: (07/10/14 to 07/09/19).

McClay, J., (PI) and Beardsley, P. M., (co-I), *Evaluating the role of ANKS1B in mediating second generation antipsychotic drug efficacy*. 2016-2017, **VCU Center for Clinical and Translational Research Endowment Fund and the National Center for CTSA (UL1TR000058) from the National Center for Advancing Translational Sciences**. Total costs: \$43,591. Project Period: (04/01/16-09/30/17).

Beardsley, P. M., (P.I.). *Evaluating the effects of SEP-363856 on prime- and cue-*

- induced reinstatement of extinguished lever pressing previously reinforced with cocaine infusion in rats.* **Sunovion Pharmaceuticals, Inc.** Total costs: \$126,574. Project Period: 2015-2017.
- Beardsley, P. M., (PI) and Harris, L. S., (orig PI until 2014). *Preclinical medications discovery and abuse liability testing for the National Institute on Drug Abuse.* **National Institute on Drug Abuse.** Total costs: \$3,712,157. Project Period: (2/22/12-2/21/17).
- Beardsley, P. M., (P.I.). *Effects of medication candidates on responding maintained by cocaine and its conditional stimuli.* **AbbVie Deutschland GmbH & Co. KG (“AbbVie”).** Total costs: \$115,520. Project Period: (2013-2014).
- Beardsley PM. Physical dependence tests with buprenorphine hemiadipate HCL in rats. **Reckitt Benckiser, Inc.** Total costs: \$83,275. Project Period: (2012-2013).
- Beardsley, P. M. Self-administration evaluation of two medication candidates. **Pfizer Inc., U.S. Pharmaceuticals Group.** Total costs: \$104,530. Project Period: (2011-2012).
- Beardsley, P. M. P. I. Assessing the Ability of Compound XXX to Prevent Relapse to Cocaine Abuse Precipitated by Cues Previously Associated with Cocaine Delivery. **Gilead Sciences, Inc.,** Palo Alto, CA. Total costs: \$33,439. Project Period: (2010-11).
- Beardsley, P. M., (PI). *Medication discovery using rat models of relapse.* **National Institute on Drug Abuse.** Total costs: \$4,364,052. Project Period: (08/28/2009 to 08/27/2014).
- Carroll, F. I. P., Beardsley, P. M., (co-I), Fennell, T., (co-I), Howard, J., (co-I) and Navarro, H., (co-I). *Selective Opioid Antagonists as Medications for Drug Abuse.* **National Institute on Drug Abuse.** Total costs: \$2,293,546. Project Period: (07/01/2010-06/30/2015).
- Beardsley, P. M., (PI) *Assessing the ability of compound XXX to prevent relapse to cocaine abuse precipitated by a stressor during abstinence.* **Research Triangle Institute International.** Total costs: \$48,466. Project Period: (2009-2010).
- Beardsley, P. M. *Evaluating URB597 for producing or potentiating THC-Like Effects.* **Merck & Co., Inc.** Total costs: \$23,983. Project Period: (2009-2010).
- Beardsley, P. M. (PI) Evaluating antibodies on methamphetamine-initiated relapse. **University of Arkansas.** Total costs: \$59,975. Project Period: (2008-2009).
- Beardsley, P. M. (PI) Modulation of cocaine's stimulus effects by dopamine D3R partial agonists. **Bioprojet SCR.** Total costs: \$61,768. Project Period: (2007-2008).
- Beardsley, P. M. (PI) Effects of Abbott receptor ligands on discriminative stimulus effects of phencyclidine in rats. **Abbott GmbH & Co. KG.** Total costs: \$35,000. Project Period: (2008).

Beardsley, P. M., (PI). *Medication discovery using rat models of relapse to cocaine self-administration*. **National Institute on Drug Abuse**. Total costs: \$5,959,435. *Project Period: (09/24/04 to 09/23/2009)*.

Beardsley, P. M. *Abuse liability assessment of GSK372475*. **GlaxoSmithKline, S.p.A.** Total costs: \$46,494. *Project Period: (12/15/2006-12/31/07)*.

van den Oord, E., (PI), Beardsley, P. M., (co-I), Robles, J. R., (co-I) and Vargas-Irwin, C., (co-I). *In silico genome scan with high-throughput addiction related phenotypes in mice*. **National Institute on Drug Abuse**. Total costs: \$409,750. *Project Period: (5/01/07-4/30/09)*.

Harris, L. S., (PI), Beardsley, P. M., (co-I), Aceto, M., (co-I) and Bowman, E. R., (co-I). *Preclinical medications discovery and abuse liability testing for the National Institute on Drug Abuse*. **NIDA**. Total costs: \$3,935,424. *Project Period: (2/22/07-2/21/12)*.

Carroll, F. I., (PI of administrative core & Project 1), Beardsley, P. M., (PI of Project 2), Kosten, T. R., (PI of Project 3) and Johanson, C.-E., (PI of Project 4). *Kappa opioid receptor antagonist for cocaine addiction*. **National Institute on Drug Abuse**. Total costs: \$3,422,062. *Project Period: (2005-2010)*.

Beardsley, P. M. *Effects of BP897 on the Conditional Stimulus Effects of Cocaine*. **Bioprojet SCR**. Total costs: \$14,900. *Project Period: (2006-2007)*.

Beardsley, P. M., (PI). *Nonclinical assessment of the abuse liability of T2000*. **Taro Pharmaceuticals, Inc.** Total costs: \$149,574. *Project Period: (2006-2007)*.

Dutta, A. K., (PI: Wayne State, MI), Beardsley, P. M., (co-I: Virginia Commonwealth Univ., Richmond, VA) and Reith, M. E., (co-I: Univ. of Illinois, Peoria, IL). *Dopamine transporter agents against cocaine dependence*. **National Institute on Drug Dependence**. Total costs: \$2,180,619. *Project Period: (09/30/05 to 08/31/2008)*.

Beardsley, P. M., (PI). *Evaluation of the CB1 antagonist, CB1XXX, for its ability to occasion the THC discriminative stimulus in rats and to maintain self-administration in rhesus monkeys*. **Merck & Co., Inc.** Total costs: \$80,552. *Project Period: (7/1/2005 to 4/30/2007)*.

Beardsley, P. M. *Abuse liability profiling of BF2-649*. **Bioprojet SCR**. Total costs: \$69,282. *Project Period: (06/1/2005-04/30/2007)*.

Beardsley, P. M., (PI). *Abuse liability profiling of L-001242178*. **Merck & Co., Inc.** Total costs: \$80,552. *Project Period: (2/1/2005 to 1/31/2007)*.

Harris, L. S., (PI), Aceto, M. D., (co-I), Beardsley, P. M., (co-I), Bowman, E. R., (co-I) and May, E. L., (co-I). *Rodent and monkey testing for NIDA Opiate Treatment Discovery Program*. **National Institute on Drug Abuse**. Total costs: \$3,546,533. *Project Period: (03/01/03 to 02/29/07)*.

- Beardsley, P. M., (PI on subcontract to Wayne State University), Dutta, A. K., (PI: Wayne State, MI), Reith, M. E., (co-I: Univ. of Illinois, Peoria, IL) and Beardsley, P. M., (co-I: Virginia Commonwealth Univ.). *Evaluation of (+)-8 and (-)-8 on cocaine-maintained responding in rhesus monkeys (supplement to NIDA R01 DA12449)*. **National Institute on Drug Abuse**. Total costs: VCU \$43,122. *Project Period: (04/01/03 to 08/31/05)*.
- van den Oord, E., (PI) and Beardsley, P. M. c.-I. *Behavioral and genetic markers of drug addiction in an adolescent murine model*. **A. D. Williams Trust Funds**. Total costs: \$14,991. *Project Period: (2004)*.
- Glennon, R. A., (PI), Beardsley, P. M., (co-I), Lichtman, A., (co-I), Young, R., (co-I), Malgorzata, D., (co-I) and Rothman, R., (co-I). *Tetrahydroisoquinolines as novel psychotherapeutic agents*. **A. D. Williams Foundation**. Total costs: \$138,641. *Project Period: (3/1/2002 to 9/1/2003)*.
- Beardsley, P. M., (P.I.). *Tests with Embutramide in mice trained to discriminate gamma-hydroxybutyric acid (GHB)*. **Phoenix Scientific, Inc.** Total costs: \$8,955. *Project Period: (07/15/02 to 07/14/03)*.
- Beardsley, P. M., (P.I.). *Self-administration tests with GW353162 in rhesus monkeys*. **GlaxoSmithKline, S.p.A.** Total costs: \$56,825. *Project Period: (07/01/02 to 06/30/02)*.
- Beardsley, P. M., (P.I.). *Drug discrimination tests with GW353162*. **GlaxoSmithKline, S.p.A.** Total costs: \$18,804. *Project Period: (08/01/02 to 07/31/03)*.
- Beardsley, P. M., (P.I.). *Progressive ratio tests with GW320659A in rhesus monkeys (supplement)*. **GlaxoSmithKline Research and Development**. Total costs: \$36,121. *Project Period: (09/01/01 to 08/31/03)*.
- Beardsley, P. M., (PI). *CNS and abuse liability profiling of embutramide*. **Phoenix Scientific, Inc.** Total costs: \$71,302. *Project Period: (7/15/01-7/14/02)*.
- Balster, R. L., (PI), Zartau, E., (co-I), Beardsley, P. M., (co-I) and Bernal, A., (co-I). *Glutamatergic mechanism of drug-conditioned behavior*. **Fogarty International Research Collaboration Award**. Total costs: \$85,016. *Project Period: (12/14/01 to 11/30/05)*.
- Balster, R. L., (PI), Beardsley, P. M., (co-I) and Cook, C., (co-I). *Interactions of stimulants and methylxanthines*. **Defense Advanced Research Projects Agency**. Total costs: \$99,845. *Project Period: (2/15/2001 to 8/14/2002)*.
- Beardsley, P. M., (PI) and Aceto, M., (co-I). *Self-administration and dependence tests with BMS-337039, Aripiprazole, in rats and monkeys*. **Bristol-Myers Squibb Company**. Total costs: \$127,890. *Project Period: (09/18/2000 to 09/17/2002)*.
- Beardsley, P. M., (PI). *Progressive ratio tests with GW320659A in rhesus monkeys*. **GlaxoWellcome Research and Development**. Total costs: \$90,305. *Project Period: (09/01/2000 to 08/31/2002)*.

Beardsley, P. M., (PI). *Medication discovery using rat models of relapse to cocaine self-administration*. **National Institute on Drug Abuse**. Total costs: (base): \$1,418,995; (with all options): \$2,812,253. *Project Period*: (09/30/2000 to 01/31/2005).

Balster, R. L., (PI), Beardsley, P. M., (co-I), Nicholson, K. L., (co-I) and Wiley, J. L., (co-I). *The behavioral pharmacology of phencyclidine*. **National Institute on Drug Dependence**. Total costs: \$2,552,273. *Project Period*: (4/1/2000 to 3/31/2005).

Beardsley, P. M., (PI) and Harris, L. S., (co-I). *Drug discrimination studies with propriam in the rat*. **Foundation for Pharmacology & Roberts Pharmaceuticals**. Total costs: \$8000. *Project Period*: (8/15/99 to 8/14/2000).

Beardsley, P. M., (PI on subcontract to Wayne State University), Dutta, A. K., (PI: Wayne State, MI), Beardsley, P. M., (co-I: Virginia Commonwealth Univ., Richmond, VA) and Reith, M. E., (co-I: Univ. of Illinois, Peoria, IL). *Dopamine transporter agents against cocaine dependence*. **National Institute on Drug Dependence**. Total costs: \$1,473,124. Total costs VCU \$265,140. *Project Period*: (09/30/99 to 08/31/2005).

Beardsley, P. M., (PI) and Balster, R. L., (co-I). *Determinants of nicotine physical dependence in the rat*. **Robert Wood Johnson Foundation, Tobacco Etiology Research Network**. Total costs: \$107,589. *Project Period*: (09/01/99 to 03/31/2002).

Beardsley, P. M., (PI). *Self-administration evaluation of GW1555 in rhesus monkeys*. **GlaxoWellcome, Inc.** Total costs: \$36,121. *Project Period*: (7/19/99 to 7/18/2000).

Sokoloff, P., (PI: INSERM, Paris), Beardsley, P. M., (co-I: Virginia Commonwealth Univ., Richmond, VA), Wermuth, C. G., (co-I: Center of Neurochem., Strasbourg) and Hoger, S., (co-I: Free Univ. of Berlin, Berlin). *Synthesis & evaluation of D3R ligands for cocaine abuse*. **National Institute on Drug Abuse**. Total costs: \$926,401; total costs VCU: \$416,748. *Project Period*: (2/1/98 to 12/31/2000).

Harris, L. S., (PI), Aceto, M. D., (co-I), Beardsley, P. M., (co-I), Bowman, E. R., (co-I) and May, E. L., (co-I). *Rodent and monkey testing for NIDA Opiate Treatment Discovery Program*. **National Institute on Drug Abuse**. Total costs: \$1,584,164. *Project Period*: (10/1/98 to 2/28/03).

Balster, R. L., (PI) and Beardsley, P. M., (co-I). *Self-administration study of (+)-transpiperidine, a cocaine treatment candidate*. **Georgetown University**. Total costs: \$20,690. *Project Period*: (08/01/98-07/31/99).

Beardsley, P. M., (PI) and Balster, R. L., (co-I). *Evaluation of the abuse potential of SR141716A*. **Sanofi Recherche**. Total costs: \$25,810. *Project Period*: (11/17/97-11/16/98).

Beardsley, P. M., (PI). *Pharmacotherapy for cocaine dependence*. **Unite e Neurobiologie et Pharmacologie Centre Paul Broca de Inserm**. Total costs: \$71,050. *Project Period*: (4/1/97 to 3/30/98).

- Beardsley, P. M., (PI) and Balster, R. L., (co-I). *Abuse potential evaluation of RTI-55. Gilford Pharmaceuticals*. Total costs: \$24,706. *Project Period: (5/1/96 to 4/30/97)*.
- Balster, R. L., (PI), Zartau, E., (co-I), Beardsley, P. M., (co-I) and Bespalov, A., (co-I). *Glutamatergic mechanism of drug-conditioned behavior. Fogarty International Research Collaboration Award*. Total costs: \$59,043. *Project Period: (4/1/96 to 3/31/99)*.
- Harris, L. S., (PI), Aceto, M. D., (co-I), Beardsley, P. M., (co-I), Bowman, E. R., (co-I) and May, E. L., (co-I). *Antinociception, physical dependence and abuse liability testing. National Institute on Drug Abuse*. Total costs: \$1,380,811. *Project Period: (9/1/95 to 8/30/98)*.
- Harris, L. S., (PI), Aceto, M. D., (co-I), Beardsley, P. M., (co-I), Bowman, E. R., (co-I) and May, E. L., (co-I). *Rodent and monkey testing for NIDA Opiate Treatment Discovery Program. National Institute on Drug Abuse*. Total costs: \$1,034,351. *Project Period: (9/1/95 to 8/30/98)*.
- Beardsley, P. M., (PI) and Balster, R. L., (co-I). *Abuse liability studies. Glaxo S.p.A.* Total costs: \$43,362. *Project Period: (6/1/95 to 8/1/97)*.
- Beardsley, P. M., (PI). *Master testing agreement, VCU-DRL (Drug Research Laboratories). Drug Research Laboratories*. Total costs: This is an open, master testing agreement with tests to be arranged ad hoc. *Project Period: (1995)*.
- Balster, R. L., (PI), Beardsley, P. M., (co-I), Wiley, J. L., (co-I) and Nicholson, K. L., (co-I). *The behavioral pharmacology of phencyclidine. National Institute on Drug Dependence*. Total costs: \$2,366,316. *Project Period: (4/1/95 to 3/31/2000)*.
- Beardsley, P. M., (PI) and Balster, R. L., (co-I). *Evaluation of RTI-89 for its cocaine-like effects in rats. Gilford Pharmaceuticals*. Total costs: \$5960. *Project Period: (3/1/94 to 2/28/95)*.
- 1988-1993** Please note: Dr. Beardsley worked in the pharmaceutical industry from 1988-1993 and grant and contract procurement was irrelevant during that period although he did maintain the NIDA award (shown immediately below) during this time..
- Beardsley, P. M. *Stimulus control of drugs of drug self-administration. National Institute on Drug Dependence. Project Period: (1988-1993)*.
- Martin, B. R., (PI), Dewey, W. L., (co-I), Harris, L. S., (co-I), Beardsley, P. M., (co-I), Rosecrans, J., (co-I) and Compton, D. R., (co-I). *Investigation of tetrahydrocannabinol receptors. National Institute on Drug Abuse. Project Period: (1987-1991)*.
- Balster, R. L., (PI), Beardsley, P. M., (co-I), Martin, B. R., (co-I) and May, E. L., (co-I). *The Behavioral pharmacology of phencyclidine. National Institute on Drug*

Abuse. *Project Period: (1987-1991).*

Harris, L. S., (PI), Dewey, W. L., (co-I), May, E. L., (co-I), Balster, R. L., (co-I), Rosecrans, J., (co-I), Martin, B. R., (co-I), Aceto, M., (co-I), Beardsley, P. M., (co-I), Zenk, P. c.-I. and Mokler, D. c.-I. *Multidisciplinary study of drugs of abuse. National Institute on Drug Abuse.* Total costs: \$1,412,152. *Project Period: (1986-1990).*

Balster, R. L. P. and Beardsley, P. M., (co-I). *Abuse potential evaluation of gepirone using intravenous self-administration in rhesus monkeys. Bristol-Myers, Inc.* Total costs: \$20,325. *Project Period: (3/1/86 to 2/28/87).*

Balster, R. L., (PI), Beardsley, P. M., (co-I) and Harris, L. S., (co-I). *Abuse potential assessment of minaprine using intravenous self-administration in rhesus monkeys. Centre de Recherches Clin Midy.* *Project Period: (1983).*

Beardsley, P. M., (PI). *Etonitazene reinforced behavior of the rat. United States Public Health Service (Individual Predoctoral National Research Service Award).* *Project Period: (1977-1981).*

Publications and presentations are included on accompanying pages.

Selected (not comprehensive, and none listed after 2000) Commissioned or Published Technical Reports and Published Abstracts

- Balster, R. L. and Beardsley, P. M. Final report on the study of the reinforcing properties of gepirone in rhesus monkeys. Technical report written on contract for the Bristol-Myers Company, Evansville, IN.
- Balster, R.L., Beardsley, P.M., and Harris, L.S. Final report of the study of the reinforcing properties of minaprine in rhesus monkeys. Technical report written on contract for Groupe Sanofi, of Clin-Midy, France.
- Balster, R.L. and Beardsley, P.M. Final report on the study of the reinforcing properties of acetorphan in rhesus monkeys. Technical report written on contract for Bioprojet, France.
- Beardsley, P.M. and Meisch, R.A. Ethanol intake in food-deprived and food-satiated rats: Effects of ethanol concentration and alternate positions of water and ethanol. Reports from the Research Laboratories, Department of Psychiatry, University of Minnesota, 1975, No. PR-75-4.
- Beardsley, P.M., Lemaire, G.A. and Meisch, R.A. Ethanol as a reinforcer under conditions of concurrent access to food and water. Reports from the Research Laboratories, Department of Psychiatry, University of Minnesota, 1978, No. PR-78-2.
- Beardsley, P.M. and Meisch, R.A. A precision drinking device with micro-metric capillary valve flow control for rats. Reports from the Research Laboratories, Department of Psychiatry, University of Minnesota, 1980, No. PR-80-1.
- Beardsley, P.M., Lemaire, G.A., and Meisch, R.A. Ethanol-maintained performance of rats under interval schedules. Reports from the Research Laboratories, Department of Psychiatry, University of Minnesota, 1983, No. PR-83-1.
- Beardsley, P.M., Balster, R.L. and Harris, L.S. Behavioral dependence of rhesus monkeys on intravenously-administered delta-9-tetrahydrocannabinol. Federation Proceedings, 1984, 43:1035.
- Beardsley, P. M., Balster, R. L. and Harris, L. S.: Behavioral dependence in rhesus monkeys following chronic THC administration. In Problems of Drug Dependence, 1984, ed. by L. S. Harris, pp. 111-117, NIDA, Rockville, MD, 1985.
- Beardsley, P.M., Kalant, H., Woodworth, I. and Stiglick, A. Effects of ethanol self-administration and withdrawal in rats responding for food and water. In: L.S. Harris (ed.) Problems of Drug Dependence 1987. NIDA, Rockville, MD., 1987.
- Balster, R., Willetts, J., Beardsley, P., Hayes, B. and Rice, A.: Excitatory amino acid neurotransmission and the behavioral pharmacology of phencyclidine-like drugs. In Problems of Drug Dependence, 1988, ed. by L. S. Harris, pp. 49, NIDA, Rockville, MD, 1989.
- Nevins, M. E., Arnolde, S. M. and Beardsley, P. M. Quantitative grip strength

assessment as a means of evaluating muscle relaxation in mice. Society for Neurosciences Abstracts, 1989, 15:1237.

- Beardsley, P. M. and Anthony, E. W. The discriminative stimulus properties of (+)-opioids do not generalize to those of morphine and have antitussive effects. Society for Neuroscience Abstracts, 1990, 16:1325.
- Nevins, M. E. and Beardsley, P. M. Characterization of the effect of antidepressants in the tail suspension test using CD-1 mice. Society for Neuroscience Abstracts, 1990, 15:914.
- Hansen, D. W., Chandrakumar, N. S., Husa, R. K., Peterson, K. B., Tsymbalov, S., Williamson, L. N., Reichman, M., and Beardsley, P. M. Tyrosyl diamides as potent mu and delta opioid receptor ligands. Society for Neuroscience Abstracts, 1992, 18:687.
- Pitzele, B.S., Chandrakumar, N. S., Contreras, P. C., Allen, S. E., Clare, M., Savage, M. A., Hammond, D. L., Nevins, M. E., Nash, S. A., Beardsley, P. M., Ragan, D., and Lanthorn, T. H. Tyrosyl amides as ligands at the phencyclidine receptor located on the NMDA-sensitive glutamate site. Society for Neuroscience Abstracts, 1992, 18:1510.
- Bloss, J. L. and Beardsley, P. M. Delta-opioid agonists, deltorphin II and DMT-DPDPE, produce physical dependence in mice. The Pharmacologist, 1992, 34:3.
- Beardsley, P. M., Lopez, O. T., and Bloss, J. L. Naltrindole (NTI) is less effective than it benzofuran analog (NTB) in attenuating morphine's discriminative stimulus, Straub tail and dependence effects. Society for Neuroscience Abstracts, 1992, 18:657.
- Beardsley, P. M., Balster, R. L., and Carroll, F. I. Evaluation of cocaine analogs more selective for dopamine uptake in rats and squirrel monkeys trained to discriminate cocaine from saline. In Problems of Drug Dependence 1994: Proceedings of the 56th Annual Scientific Meeting The College on Problems of Drug Dependence, Inc., ed. by L. S. Harris, pp. 382, National Institute on Drug Abuse, Rockville, MD, 1995. .
- Beardsley, P. M. and Harris, L. S.: Dihydroetorphine (DHE) potently generates self-administration and heroin-like stimulus effects. In Problems of Drug Dependence 1996: Proceedings of the 58th Annual Scientific Meeting The College on Problems of Drug Dependence, Inc., ed. by L. S. Harris, pp. 95, National Institute on Drug Abuse, Rockville, MD, 1997.
- Beardsley, P. M. and Martin, B. R.: SR141716A precipitates suppression of operant response rates in THC chronically treated rats. In Problems of Drug Dependence 1997: Proceedings of the 59th Annual Scientific Meeting The College on Problems of Drug Dependence, Inc., ed. by L. S. Harris, pp. 95, National Institute on Drug Abuse, Rockville, MD, 1998.
- Bespalov, A. Y., Balster, R. L. and Beardsley, P. M.: NMDA receptor antagonists attenuate tolerance to morphine's discriminative stimulus effects. In Problems of Drug Dependence 1997: Proceedings of the 59th Annual Scientific Meeting The

College on Problems of Drug Dependence, Inc., ed. by L. S. Harris, pp. 110, National Institute on Drug Abuse, Rockville, MD, 1998.

Willmore, C. B., Bespalov, A. Y., Balster, R. L. and Beardsley, P. M.: Morphine-like stimulus effects of NMDA antagonists may be due to disruption of stimulus control. In Problems of Drug Dependence 1998: Proceedings of the 60th Annual Scientific Meeting The College on Problems of Drug Dependence, Inc., ed. by L. S. Harris, pp. 232, National Institute on Drug Abuse, Rockville, MD, 1999.

Beardsley, P. M. and Harris, L. S.: Dopamine/opiate-active N-Butyrophenone prodine-like compounds produce heroin's stimulus effects. In Problems of Drug Dependence 1998: Proceedings of the 60th Annual Scientific Meeting The College on Problems of Drug Dependence, Inc., ed. by L. S. Harris, pp. 60, National Institute on Drug Abuse, Rockville, MD, 1999.

Beardsley, P. M. and Balster, R. L.: The glycine antagonist, GV150526, does not have PCP-like discriminative stimulus effects and is not self-administered. Behavioural Pharmacology 9(Supplement 1): S14, 1999.

Beardsley, P. M.: Is there a role for dopamine D3R agents in drug abuse?. Behavioural Pharmacology 10 (Supplement 1): S6-S7, 1999.

Beardsley, P. M., McCann, D. and Harris, L. S.: Effects of selegiline on heroin- and food-maintained performances in rhesus monkeys. Drug and Alcohol Dependence, 60 (Supplement): S13, 2000.

Dutta, A. K., Fei, X.-S., Beardsley, P. M. and Reith, M. A.: Novel N- and O-substituted 4-[[2-(diphenylmethoxy)-ethyl]-1-[(phenyl)methyl]piperidine analogs. Drug and Alcohol Dependence, 60 (Supplement): S55, 2000.

Publications

Bachtell, R. K., Jones, J. D., Heinzerling, K. G., Beardsley, P. M. and Comer, S. D., (In press). Glial and neuroinflammatory targets for treating substance use disorders. *Drug & Alcohol Dependence*.

Enga, R. M., Rice, A. C., Weller, P., Subler, M. A., Lee, D., Hall, C. P., Windle, J. J., Beardsley, P. M., van den Oord, E. J. and McClay, J. L., (2017). Initial characterization of behavior and ketamine response in a mouse knockout of the post-synaptic effector gene *Anks1b*. *Neurosci Lett* 641, 26-32.

Owens, R. A., Ignatowska-Jankowska, B., Mustafa, M., Beardsley, P. M., Wiley, J. L., Jali, A., Selley, D. E., Niphakis, M. J., Cravatt, B. F. and Lichtman, A. H., (2016). Discriminative stimulus properties of the endocannabinoid catabolic enzyme inhibitor SA-57 in mice. *Journal of Pharmacology & Experimental Therapeutics* 358, 306-314.

Poland, R. S., Hahn, Y. K., Knapp, P. E., Beardsley, P. M. and Bowers, M. S., (2016). Ibudilast attenuates expression of behavioral sensitization to cocaine in male and female rats. *Neuropharmacology* 109, 281-292.

- Wiebelhaus, J. M., Walentiny, D. M. and Beardsley, P. M. (2016) Effects of acute and repeated administration of oxycodone and naloxone-precipitated withdrawal on intracranial self-stimulation in rats. *Journal of Pharmacology and Experimental Therapeutics* 356:43-52.
- Fitting, S., Stevens, D. L., Khan, F. A., Scoggins, K. L., Enga, R. M., Beardsley, P. M., Knapp, P. E., Dewey, W. L. and Hauser, K. F., (2016). Morphine tolerance and physical dependence are altered in conditional HIV-1 Tat transgenic mice. *J Pharmacol Exp Ther* 356, 96-105.
- Vengeliene, V., Moeller, A., Meinhardt, M. W., Beardsley, P. M., Sommer, W. H., Spanagel, R. and Bespalov, A., (2016). The Calpain Inhibitor A-705253 Attenuates Alcohol-Seeking and Relapse with Low Side-Effect Profile. *Neuropsychopharmacology* 41, 979-988.
- Bespalov, A., Beardsley, P. M. and Todtenkopf, M. S., (2015). Utility of intracranial self-stimulation in the assessment of the abuse liability of new pharmaceuticals In: *Nonclinical Assessment of Abuse Potential for New Pharmaceuticals*, Vol. 1, eds. Compton, D. C., Hudzik, T. J. and Markgraf, C. G. (Elsevier, Inc., New York) p. 197-213.
- McClay, J. L., Vunck, S. A., Batman, A. M., Crowley, J. J., Vann, R. E., Beardsley, P. M. and van den Oord, E. J., (2015). Neurochemical Metabolomics Reveals Disruption to Sphingolipid Metabolism Following Chronic Haloperidol Administration. *J Neuroimmune Pharmacol* 10, 425-434.
- Wiley, J.L., Walentiny, D.M., Wright, M.J., Jr., Beardsley, P.M., Burston, J.J., Poklis, J.L., Lichtman, A.H. and Vann, R.E. (2014). Endocannabinoid contribution to Δ^9 -tetrahydrocannabinol discrimination in rodents. *European Journal of Pharmacology*
- Beardsley, P. M., & Hauser, K. F. (2014). Glial modulators as potential treatments of psychostimulant abuse. *Advances in Pharmacology*, 69, 1-69. doi: 10.1016/B978-0-12-420118-7.00001-9
- El-Hage, N., Rodriguez, M., Podhaizer, E.M., Zou, S., Dever, S.M., Snider, S.E., Knapp, P.E., Beardsley, P.M. & Hauser, K.F. (2014) Ibudilast (AV411), and its AV1013 analog, reduce HIV-1 replication and neuronal death induced by HIV-1 and morphine. *AIDS*.
- Bespalov, A. Y., (А.Ю. Беспалова), Zvartau, E. E., (Э.Э. Звартан), Beardsley, P. M., (П.Бирдсли) and Katz, J. L., (Дж. Катца) (Eds.) (2013). *Textbook on Behavioral Pharmacology (Фармакология поведения)*. Pavlov Medical University Press (Издательство СПбГМУ им. И.П. Павлова), St. Petersburg, (Санкт-Петербург) Russia (Россия).
- Snider, S. E., Hendrick, E. S., & Beardsley, P. M. (2013). Glial cell modulators attenuate methamphetamine self-administration in the rat. *Eur J Pharmacol*, 701(1-3), 124-130.

- Adkins, D.E., McClay, J.L., Vunck, S.A., Batman, A.M., Vann, R.E., Clark, S.L., Souza, R.P., Crowley, J.J., Sullivan, P.F., van den Oord, E.J. and Beardsley, P.M. (2013). Behavioral metabolomics analysis identifies novel neurochemical signatures in methamphetamine sensitization. *Genes Brain Behav*, **12**, 780-91.
- Aberg, K. A., Xie, L. Y., McClay, J. L., Nerella, S., Vunck, S., Snider, S., Beardsley, P. M. and van den Oord, E. J., (2013). Testing two models describing how methylome-wide studies in blood are informative for psychiatric conditions. *Epigenomics* **5**, 367-377.
- Uguen, M., Perrin, D., Belliard, S., Ligneau, X., Beardsley, P. M., Lecomte, J. M. and Schwartz, J. C., (2013). Preclinical evaluation of the abuse potential of Pitolisant, a histamine H(3) receptor inverse agonist/antagonist compared with Modafinil. *British Journal of Pharmacology* **169**, 632-644.
- Shelton, K. L., Hendrick, E. S. and Beardsley, P. M., (2013). Efficacy of buspirone for attenuating cocaine and methamphetamine reinstatement in rats. *Drug and Alcohol Dependence* **129**, 210-216.
- Beardsley, P. M. and Shelton, K. L., (2012). Prime-, stress-, and cue-induced reinstatement of extinguished drug-reinforced responding in rats: cocaine as the prototypical drug of abuse. *Curr Protoc Neurosci* Chapter 9, 1-40.
- McClay, J. L., Adkins, D. E., Vunck, S. A., Batman, A. M., Vann, R. E., Clark, S. L., Beardsley, P. M. and van den Oord, E. J., (2013). Large-scale neurochemical metabolomics analysis identifies multiple compounds associated with methamphetamine exposure. *Metabolomics* **9**, 392-402.
- Snider, S. E., Vunck, S. A., van den Oord, E. J., Adkins, D. E., McClay, J. L. and Beardsley, P. M., (2012). The glial cell modulators, ibudilast and its amino analog, AV1013, attenuate methamphetamine locomotor activity and its sensitization in mice. *European Journal of Pharmacology* **679**, 75-80.
- McClay, J. L., Adkins, D. E., Aberg, K., Bukszar, J., Khachane, A. N., Keefe, R. S., Perkins, D. O., McEvoy, J. P., Stroup, T. S., Vann, R. E., Beardsley, P. M., Lieberman, J. A., Sullivan, P. F. and van den Oord, E. J., (2011). Genome-wide pharmacogenomic study of neurocognition as an indicator of antipsychotic treatment response in schizophrenia. *Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology* **36**, 616-626.
- Beardsley, P. M., (in press). Behavioral Dependence. In: Behavioral Pharmacology (Фармакология поведения), eds. Beshpalov, A. Y., (А.Ю. Беспалов), Zvartau, E. E., (Э.Э. Звартау), Beardsley, P. M., (П.М. Бирдсли) and Katz, J. L., (Дж.Л.Кац) (Pavlov Medical University Press (Издательство СПбГМУ им. И.П. Павлова), Behavioral Pharmacology (Фармакология поведения)).
- Batman, A. M., Dutta, A. K., Reith, M. E. and Beardsley, P. M., (2010). The selective dopamine uptake inhibitor, D-84, suppresses cocaine self-administration, but does not occasion cocaine-like levels of generalization. *European Journal of Pharmacology* **648**, 127-132.

- Brunzell, D. H., Boschen, K. E., Hendrick, E. S., Beardsley, P. M. and McIntosh, J. M., (2010). alpha-Conotoxin MII-sensitive nicotinic acetylcholine receptors in the nucleus accumbens shell regulate progressive ratio responding maintained by nicotine. *Neuropsychopharmacology* 35, 665-673.
- Beardsley, P. M., Shelton, K. L., Hendrick, E. and Johnson, K. W., (2010). The glial cell modulator and phosphodiesterase inhibitor, AV411 (ibudilast), attenuates prime- and stress-induced methamphetamine relapse. *European Journal of Pharmacology*. 637, 102-108.
- Beardsley, P. M., Pollard, G. T., Howard, J. L. and Carroll, F. I., (2010). Effectiveness of analogs of the kappa opioid receptor antagonist (3R)-7-Hydroxy-N-((1S)-1-(((3R,4R)-4-(3-hydroxyphenyl)-3,4-dimethyl-1-piperidyl)methyl)-2-methylpropyl)-1,2,3,4-tetrahydro-3-isoquinolinecarboxamide (JDtic) to reduce U50,488-induced diuresis and stress-induced cocaine reinstatement in rats. *Psychopharmacology* 210, 189-198.
- Beardsley, P. M., (2009). Evaluation of Taranabant (MK-0364) for its Self-Administration in Rhesus Monkeys and for its Discriminative Stimulus Effects in Rats. *Drug Development Research* 70, 577-584.
- Kharkar, P. S., Batman, A., Zhen, J., Beardsley, P. M., Reith, M. E. and Dutta, A. K., (2009). Synthesis and biological characterization of (3R,4R)-4-(2-(benzhydryloxy)ethyl)-1-((R)-2-hydroxy-2-phenylethyl)-piperidin-3-ol and its stereoisomers for monoamine transporters. *ChemMedChem* 4, 1075-1085.
- Beardsley, P. M., Thomas, B. F. and McMahon, L. R., (2009). Cannabinoid CB1 receptor (CB1R) antagonists as potential pharmacotherapies for drug abuse disorders. *International Review of Psychiatry* 21, 134-142.
- Shelton, K. L. and Beardsley, P. M., (2008). Effect of drug-paired exteroceptive stimuli presentations on methamphetamine reinstatement in rats. *Pharmacology Biochemistry and Behavior* 90, 434-440.
- Beardsley, P. M., (2007). Assessing dependency and abuse potential. In: *Nonclinical Drug Safety Assessment: Practical Considerations for Successful Registration*, eds. Sietsema, W. K. and Schwen, R. (FDAnews, Falls Church, VA) p. 441-463.
- Vargas-Irwin, C., van den Oord, E. J., Beardsley, P. M. and Robles, J. R., (2006). A method for analyzing strain differences in acquisition of IV cocaine self-administration in mice. *Behavior Genetics* 36, 525-535.
- Newman, J. L. and Beardsley, P. M., (2006). Effects of memantine, haloperidol, and cocaine on primary and conditioned reinforcement associated with cocaine in rhesus monkeys. *Psychopharmacology* 185, 142-149.
- Cook, C. D., Biddlestone, L., Coop, A. and Beardsley, P. M., (2006). Effects of combining ethanol (EtOH) with gamma-hydroxybutyrate (GHB) on the discriminative stimulus, locomotor, and motor-impairing functions of GHB in mice. *Psychopharmacology* 185, 112-122.

- Vann, R. E., Balster, R. L. and Beardsley, P. M., (2005). Dose, duration, and pattern of nicotine administration as determinants of behavioral dependence in rats. *Psychopharmacology*, 1-12.
- Shelton, K. L. and Beardsley, P. M., (2005). Interaction of extinguished cocaine-conditioned stimuli and footshock on reinstatement. *International Journal of Comparative Psychology* 18, 154-166.
- Newman, J. L. and Beardsley, P. M., (2005). Dose history and occurrence of conditional stimuli determine the strength of cocaine-seeking behavior of rhesus monkeys. *International Journal of Comparative Psychology* 18, 126-140.
- Beardsley, P. M. and Thomas, B. F., (2005). Current evidence supporting a role of cannabinoid CB1 receptor (CB1R) antagonists as potential pharmacotherapies for drug abuse disorders. *Behavioural Pharmacology* 16, 275-296.
- Beardsley, P. M., Howard, J. L., Shelton, K. L. and Carroll, F. I., (2005). Differential effects of the novel kappa opioid receptor antagonist, JDTic, on reinstatement of cocaine-seeking induced by footshock stressors vs cocaine primes and its antidepressant-like effects in rats. *Psychopharmacology* 183, 118-126.
- Batman, A. M., Munzar, P. and Beardsley, P. M., (2005). Attenuation of nicotine's discriminative stimulus effects in rats and its locomotor activity effects in mice by serotonergic 5-HT_{2A/2C} receptor agonists. *Psychopharmacology* 179, 393-401.
- Shelton, K. L., Hendrick, E. and Beardsley, P. M., (2004). Interaction of noncontingent cocaine and contingent drug-paired stimuli on cocaine reinstatement. *European Journal of Pharmacology* 497, 35-40.
- Kolhatkar, R., Cook, C. D., Ghorai, S. K., Deschamps, J., Beardsley, P. M., Reith, M. E. and Dutta, A. K., (2004). Further structurally constrained analogues of cis-(6-benzhydrylpiperidin-3-yl)benzylamine with elucidation of bioactive conformation: discovery of 1,4-diazabicyclo[3.3.1]nonane derivatives and evaluation of their biological properties for the monoamine transporters. *Journal of Medicinal Chemistry* 47, 5101-5113.
- Cook, C. D., Newman, J. L., Winfree, J. C. and Beardsley, P. M., (2004). Modulation of the locomotor activating effects of the noncompetitive NMDA receptor antagonist MK801 by dopamine D_{2/3} receptor agonists in mice. *Pharmacology Biochemistry and Behavior* 77, 309-318.
- Cook, C. D. and Beardsley, P. M., (2004). I. Modulation of the Discriminative Stimulus Effects of Mu Opioid Agonists in Rats: Effects of Dopamine D_{2/3} Antagonists. *Behavioral Pharmacology* 15, 65-74.
- Cook, C. D. and Beardsley, P. M., (2004). II. Modulation of the Discriminative Stimulus Effects of Mu Opioid Agonists in Rats: Effects of Dopamine D_{2/3} Agonists. *Behavioral Pharmacology* 15, 75-83.
- Beardsley, P. M., Aceto, M. D., Cook, C. D., Bowman, E. R., Newman, J. L. and Harris, L. S., (2004). Discriminative stimulus, reinforcing, physical dependence and

- antinociceptive effects of oxycodone in mice, rats and rhesus monkeys. *Experimental and Clinical Psychopharmacology* 12, 163-172.
- Kozikowski, A. P., Johnson, K. M., Deschaux, O., Bandyopadhyay, B. C., Araldi, G. L., Carmona, G., Munzar, P., Smith, M. P., Balster, R. L., Beardsley, P. M. and Tella, S. R., (2003). Mixed cocaine agonist/antagonist properties of (+)-methyl 4-(4-chlorophenyl)-1-methylpiperidine-3a-carboxylate [(+)-CPCA], a piperidine based analog of cocaine. *Journal of Pharmacology and Experimental Therapeutics* 305, 143-150.
- Ghorai, S. K., Cook, C. D., Davis, M., Venkataraman, S. K., George, C., Beardsley, P. M., Reith, M. E. A. and Dutta, A. K., (2003). High affinity hydroxy piperidine analogues of 4-(2-benzhydryloxy-ethyl)-1-(4-fluoro-benzyl)-piperidine for the dopamine transporter: Stereospecific interactions in vitro and in vivo. *Journal of Medicinal Chemistry* 46, 1220-1228.
- Cook, C. D. and Beardsley, P. M., (2003). The modulatory actions of dopamine D2/3 agonists and antagonists on the locomotor-activating effects of morphine and caffeine in mice. *Pharmacology Biochemistry and Behavior* 75, 363-371.
- Willmore, C. B., Bespalov, A. Y. and Beardsley, P. M., (2002). Site-Selective N-Methyl-D-Aspartate and α -Amino-3-Hydroxy-5-Methyl-4-Isoxazolepropionate Antagonists Produce Distinct Effects in Rats Performing Complex Discriminations. *Neurobiology of Learning and Memory* 78, 347-364.
- Newman, J. L., Vann, R. E., May, E. L. and Beardsley, P. M., (2002). Heroin discriminative stimulus effects of methadone, LAAM and other isomers of acetylmethadol in rats. *Psychopharmacology* 164, 108-114.
- Dutta, A. K., Matthew Davis, Fei, X.-S., Beardsley, P. M., Cook, C. D. and Reith, M. E. A., (2002). Expansion of structure-activity studies of piperidine analogues of 1-[2-(Diphenylmethoxy)ethyl]-4-(3-phenylpropyl)piperazine (GBR 12935) compounds by altering substitutions in the N-benzyl moiety and behavioral pharmacology of selected molecules. *Journal of Medicinal Chemistry* 45, 654-662.
- Cook, C. D., Carroll, F. I. and Beardsley, P. M., (2002). RTI 112, a 3-Phenyltropane analog, produces long-lasting cocaine-like discriminative stimulus effects in rats and squirrel monkeys. *European Journal of Pharmacology* 442, 93-98.
- Cook, C. D., Aceto, M. D., Coop, A. and Beardsley, P. M., (2002). Effects of the putative antagonist, NCS382, on the behavioral pharmacological actions of gammahydroxybutyrate (GHB). *Psychopharmacology* 160, 99-106.
- Beardsley, P. M., Ratti, E., Balster, R. L., Willetts, J. and Trist, D., (2002). The selective glycine antagonist gavestinel lacks phencyclidine-like behavioral effects. *Behavioural Pharmacology* 13, 583-592.
- Beardsley, P. M., Dance, M. E., Balster, R. L. and Munzar, P., (2002). Evaluation of the reinforcing effects of the cannabinoid CB₁ receptor antagonist, SR141716A, in rhesus monkeys. *European Journal of Pharmacology* 435, 209-216.

- Willmore, C. B., Bespalov, A. Y. and Beardsley, P. M., (2001). Competitive and noncompetitive NMDA antagonist effects in rats trained to discriminate lever press counts. *Pharmacology Biochemistry and Behavior* 69, 493-502.
- Dutta, A. K., Fei, X.-S., Beardsley, P. M., Newman, J. L. and Reith, M. E. A., (2001). Structure-activity relationship studies of 4-[2-(Diphenylmethoxy)ethyl]-1-benzylpiperidine derivatives and their N-analogs: Evaluation of behavioral activity of O- and N-analogs and their binding to monoamine transporters. *Journal of Medicinal Chemistry* 44, 937-948.
- Cook, C. D., Carroll, F. I. and Beardsley, P. M., (2001). Cocaine-like discriminative stimulus effects of novel cocaine and 3-phenytropane analogs in the rat. *Psychopharmacology* 159, 58-63.
- Bespalov, A. Y., Zvartau, E. E. and Beardsley, P. M., (2001). Opioid-NMDA receptor interactions may clarify conditioned (associative) components of opioid analgesic tolerance. *Neurosciences and Biobehavioral Reviews* 25, 343-353.
- Beardsley, P. M., Sokoloff, P., Balster, R. L. and Schwartz, J.-C., (2001). The D3R partial agonist, BP 897, attenuates the discriminative stimulus effects of cocaine and amphetamine and is not self-administered. *Behavioural Pharmacology* 12, 1-11.
- Bespalov, A. Y., Zvartau, E. E., Balster, R. L. and Beardsley, P. M., (2000). Effects of NMDA receptor antagonists on reinstatement of cocaine-seeking behavior by priming injections of cocaine or exposures to cocaine-associated cues in rats. *Behavioural Pharmacology* 11, 37-44.
- Bespalov, A. Y., Dravolina, O. A., Zvartau, E. E., Beardsley, P. M. and Balster, R. L., (2000). Effects of NMDA receptor antagonists on cocaine-conditioned motor activity in rats. *European Journal of Pharmacology* 390, 303-311.
- Beardsley, P. M. and Martin, B. R., (2000). Effects of the cannabinoid CB1 receptor antagonist, SR141716A, after Δ^9 -tetrahydrocannabinol withdrawal. *European Journal of Pharmacology* 387, 47-53.
- Bespalov, A. Y., Tokarz, M. E., Bowen, S. E., Balster, R. L. and Beardsley, P. M., (1999). Effects of test conditions on the outcome of place conditioning with morphine and naltrexone in mice. *Psychopharmacology* 141, 118-122.
- Bespalov, A. Y., Balster, R. L. and Beardsley, P. M., (1999). N-methyl-D-aspartate receptor antagonists and the development of tolerance to the discriminative stimulus effects of morphine in rats. *Journal of Pharmacology and Experimental Therapeutics* 290, 20-27.
- Beardsley, P. M. and Kelly, T. H., (1999). Acute effects of cannabis on human behavior and central nervous system functions. In: *The Health Effects of Cannabis*, eds. Kalant, H., Corrigall, W. A., Hall, W. and Smart, R. G. (Centre for Addiction and Mental Health, Toronto) p. 127-170.
- Cook, C. D., Carroll, F. I. and Beardsley, P. M., (1998). Separation of the locomotor

- stimulant and discriminative stimulus effects of cocaine by its C-2 phenyl ester analog, RTI-15. *Drug and Alcohol Dependence* 50, 123-128.
- Bespalov, A. Y., Beardsley, P. M. and Balster, R. L., (1998). Interactions between N-methyl-D-aspartate receptor antagonists and the discriminative stimulus effects of morphine in rats. *Pharmacology Biochemistry and Behavior* 60, 507-517.
- Beardsley, P. M. and Harris, L. S., (1997). Evaluation of the discriminative stimulus and reinforcing effects of dihydroetorphine. *Drug and Alcohol Dependence* 48, 77-84.
- Kelly, T. H. and Beardsley, P. M., (1996). Experimental studies of the acute effects of marijuana on human behavior. *The Advocate* 18, 36-57.
- Beardsley, P. M., Balster, R. L. and Harris, L. S., (1996). Evaluation of the discriminative stimulus and reinforcing effects of gammahydroxybutyrate (GHB). *Psychopharmacology* 127, 315-322.
- Tessari, M., Valerio, E., Chiamulera, C. and Beardsley, P. M., (1995). Nicotine reinforcement in rats with histories of cocaine self-administration. *Psychopharmacology* 121, 282-283.
- Beardsley, P. M., Lopez, O. T., Gullikson, G. and Flynn, D., (1994). Serotonin 5-HT₃ antagonists fail to affect ethanol self-administration of rats. *Alcohol* 11, 389-395.
- Nevins, M. E., Nash, S. A. and Beardsley, P. M., (1993). Quantitative grip strength assessment as a means of evaluating muscle relaxation in mice. *Psychopharmacology* 110, 92-96.
- Chandrakumar, N. S., Carron, C. P., Meyer, D. M., Beardsley, P. M., Nash, S. A., Tam, L. L. and Rafferty, M., (1993). Phenylphosphonate monoester analogs of cocaine. Potential haptens for the generation of catalytic antibodies. *Bioorganic Medicinal Chemistry Letters* 3, 309-312.
- Beardsley, P. M., Lemaire, G. A. and Meisch, R. A., (1993). Persistence of ethanol self-administration as a function of interreinforcer interval and concentration. *Drug and Alcohol Dependence* 34, 71-81.
- Beardsley, P. M. and Balster, R. L., (1993). The effects of delay of reinforcement and dose on the self-administration of cocaine and procaine in rhesus monkeys. *Drug and Alcohol Dependence* 34, 37-43.
- Chandrakumar, N. S., Stapelfeld, A., Beardsley, P. M., Lopez, O. T., Drury, B., Anthony, E., Savage, M. A., Williamson, L. N. and Reichman, M., (1992). Analogs of the delta opioid receptor selective cyclic peptide (2-D- penicillamine,5-D- penicillamine)-enkephalin: 2',6'-Dimethyltyrosine and Gly sup 3-Phe sup 4 amide bond isostere substitutions. *Journal of Medicinal Chemistry* 35, 2928-2938.
- Beardsley, P. M. and Balster, R. L., (1992). The intravenous self-administration of antihistamines by rhesus monkeys. *Drug and Alcohol Dependence* 30, 117-126.
- Beardsley, P. M., Anthony, E. W. and Lopez, O. T., (1992). Phencyclidine established as

- a discriminative stimulus using ethanol as a reinforcer. *Behavioral Pharmacology* 3, 497-505.
- Beardsley, P. M., Hayes, B. A. and Balster, R. L., (1990). The self-administration of MK-801 can depend upon drug-reinforcement history, and its discriminative stimulus properties are phencyclidine-like in rhesus monkeys. *Journal of Pharmacology and Experimental Therapeutics* 252, 953-959.
- Woolverton, W. L., Ator, N. A., Beardsley, P. M. and Carroll, M. E., (1989). Effects of environmental conditions on the psychological well-being of primates: A review of the literature. *Life Sciences* 44, 901-917.
- Knisely, J. S., Beardsley, P. M., Aceto, M. D., Balster, L. and Harris, L. S., (1989). Assessment of the abuse potential of aceto-rphan, an enkephalinase inhibitor. *Drug and Alcohol Dependence* 23, 143-151.
- Martin, B. R., Compton, D. R., Little, P. J. and Beardsley, P. M., (1988). Pharmacological evaluation of agonistic and antagonistic activity of cannabinoids. In: *Structure-Activity Relationships of the Cannabinoids*, eds. Rapaka, R. S. and Makriyannis, A. (NIDA, Rockville, MD) p. 108-122.
- Beardsley, P. M. and Balster, R. L., (1988). Evaluation of antagonists of the discriminative stimulus and response rate effects of phencyclidine. *Journal of Pharmacology and Experimental Therapeutics* 244, 34-40.
- Beardsley, P. M., Scimeca, J. A. and Martin, B. R., (1987). Studies on the agonistic activity of Δ^{9-11} -tetrahydrocannabinol in mice, dogs and rhesus monkeys and its interactions with D^9 -tetrahydrocannabinol. *Journal of Pharmacology and Experimental Therapeutics* 241, 521-526.
- Beardsley, P. M., Balster, R. L. and Salay, J. M., (1987). Separation of the response rate and discriminative stimulus effects of phencyclidine: Training dose as a factor in phencyclidine-saline discrimination. *Journal of Pharmacology and Experimental Therapeutics* 241, 159-165.
- Beardsley, P. M. and Balster, R. L., (1987). Self-administration of minaprine in rhesus monkeys. *Drug and Alcohol Dependence* 19, 121-129.
- Beardsley, P. M. and Balster, R. L., (1987). Behavioral dependence upon phencyclidine and ketamine in the rat. *Journal of Pharmacology and Experimental Therapeutics* 242, 203-211.
- Beardsley, P. M., Balster, R. L. and Harris, L. S., (1986). Self-administration of methylenedioxymethamphetamine (MDMA) by rhesus monkeys. *Drug and Alcohol Dependence* 18, 149-157.
- Beardsley, P. M., Balster, R. L. and Harris, L. S., (1986). Dependence on tetrahydrocannabinol in rhesus monkeys. *Journal of Pharmacology and Experimental Therapeutics* 239, 311-319.
- Beardsley, P. M., Lemaire, G. A. and Meisch, R. A., (1983). Effects of minimum-

interreinforcer interval on ethanol-maintained performance of rats. *Pharmacology Biochemistry and Behavior* 19, 843-847.

Beardsley, P. M. and Meisch, R. A., (1981). A precision drinking device for rats tested with water etonitazene and ethanol. *Pharmacology Biochemistry and Behavior* 14, 871-876.

Beardsley, P. M., Lemaire, G. A. and Meisch, R. A., (1978). Ethanol-reinforced behavior of rats with concurrent access to food and water. *Psychopharmacology* 59, 7-11.

Meisch, R. A. and Beardsley, P., (1975). Ethanol as a reinforcer for rats: effects of concurrent access to water and alternate positions of water and ethanol. *Psychopharmacologia* 43, 19-33.

Selected (not comprehensive) Presentations

- Beardsley, P. M., (2016). *Introduction to the NPS issues and the status of the International Regulatory Response*. Presentation at: **College on Problems of Drug Dependence Meeting; Workshop: International Emergence and Abuse of New Psychotropic Substances (NPS), Their Toxicity and the Current Regulatory Response**, in Palm Springs, CA.
- Beardsley, P. M., (2016). *Preclinical effectiveness of glial and neuroinflammatory modulators for attenuating some abuse-related effects of drugs (invited address, invited co-chair)*. Presentation at: **Behavior, Biology, and Chemistry: Translational Research in Addiction**, in San Antonio, Texas, U.S.A.
- Enga, R. M. and Beardsley, P. M., (2015). *Precipitated oxycodone withdrawal reduces the startle reflex and bodyweight in C57BL/6J and control mice, but not in HIV-1 Tat-expressing mice*. Invited presentation at: **International Narcotics Research Conference, in Phoenix, AZ**.
- Enga, R. M. and Beardsley, P. M., (2015). *Progress in establishing oxycodone as an oral reinforcer in mice*. Presentation at: **International Study Group Investigating Drugs as Reinforcers, in Phoenix, AZ**.
- El-Hage, N., Zou, S., Snyder, S., Podhaizer, E. M., Beardsley, P. M., Knapp, P. E. and Hauser, K. F., (2013). *Neuroprotective role of phosphodiesterase inhibitor ibudilast on neuronal cell death induced by HIV-1 and morphine activated glia*. **19th SNIP Conference, in San Juan, Puerto Rico**.
- Beardsley, P. M. (2013). *Preclinical evidence that chemically modulating glial and neuroinflammatory activity affects drug-maintained and relapse behavior with a focus on methamphetamine* **College on Problems of Drug Dependence. Hollywood, FL**.
- Beardsley, P. M. and Bergman, J., (2013). *Behavioral dependence (invited keynote address)*. Presentation at: **Winter Conference on Animal Learning and Behavior**, in Winter Park, CO.
- Beardsley, P. M., (2012). *Drug Abuse Considerations in Anesthetic Practice: Concerns for Patients as well as Practitioners (invited address)*. Presentation at: **Nurse Anesthesiology Faculty Associates 36th Annual Anesthesia Conference**, in Williamsburg, VA.
- Beardsley, P. M., (2012). *Nonclinical Abuse Liability Assessments (invited address)*. Presentation at: **Abuse Liability Conference, Eli Lilly and Company**, in Indianapolis, IN.
- Snider, S. E., Vunck, S. A., Hendrick, E. and Beardsley, P. M., (2012). *Ibudilast and AV1013 attenuate methamphetamine self-administration in rats*. Presentation at: **International Study Group Investigating Drugs as Reinforcers 2012 Annual Meeting**, in Palm Springs, CA.

- Vunck, S. A., Snider, S. E. and Beardsley, P. M., (2012). *Effects of mu and kappa opioid receptor ligands on the expression and extinction of conditioned fear in C57BL/6j mice*. Presentation at: **College on Problems of Drug Dependence 74th Annual Meeting**, in Palm Springs, CA.
- Beardsley, P. M., (2011). *Discontinuation phenomena* (invited address). Presentation at: **Science of Abuse Liability Assessment**, in Rockville, MD.
- Aberg, K., McClay, J., Rudolf, G., Nerella, S., Bukszar, J., Xie, L., Hudson, A., Khachane, A., Vunck, S., Snider, S., Beardsley, P., Hultman, C., Magnusson, P. K., Sullivan, P. and Oord, E. v. d., (2011). *Large Scale Genome-Wide Methylation Analysis of Schizophrenia*. Presentation at: **American Society of Human Genetics**, in Montreal, Canada.
- Vunck, S. A., Snider, S. E., Oord, E. J. C. G. v. d. and Beardsley, P. M., (2011). *The kappa opioid receptor agonist, U50,488, exacerbates conditioned fear in mice*. Presentation at: **Experimental Biology 2011**, in Washington, D.C.
- Snider, S. E., Vunck, S. A., Oord, E. J. C. G. v. d., Adkins, D. E., McClay, J. L. and Beardsley, P. M., (2011). *Glial modulatory drugs, AV411 (ibudilast) and AV1013, blunt methamphetamine-induced locomotor activation and sensitization in mice*. Presentation at: **Experimental Biology 2011**, in Washington, D.C.
- Beardsley, P. M., (2011). *The reinforcing and discriminative stimulus effects of the (+)-(2S,3S)-hydroxymetabolite of bupropion in rhesus monkeys and mice*. Presentation at: **College on Problems of Drug Dependence**, in Hollywood, FL.
- Beardsley, P. M., Pollard, G. T., Howard, J. L. and Carroll, F. I., (2010). *Novel JDTic analogues block kappa opioid receptor (KOR) agonist-induced diuresis and attenuate stress-induced cocaine reinstatement*. Presentation at: **College on Problems of Drug Dependence**, in Scottsdale, AZ.
- Beardsley, P. M., (2011). *Effects of AV411 & AV1013 on methamphetamine-associated behaviors in the rat*. Presentation at: **Ibudilast (AV411/MN-166) Addiction R & D Summit** in National Institute on Drug Abuse, Rockville, MD.
- Beardsley, P. M., (2009). *Limitations of current preclinical abuse assessment strategies and possible future approaches* (invited workshop presentation). Presentation at: **College on Problems of Drug Dependence, Abuse Liability Workshop**, in Reno, NV.
- McClay, J. L., Aberg, K., Adkins, D. E., Bukszár, J., Zhao, Z., Vladimirov, V. I., Lieberman, J. A., Sullivan, P. F., Beardsley, P. M. and van den Oord, E. JCD., (2009). *Individualized Antipsychotic Therapy For Schizophrenic Patients*. Presentation at: **Pharmacogenomics & Personalized Medicines**, in Cold Spring Harbor, NY.
- Beardsley, P. M., (2008). *Assessment of abuse potential of cannabinoid-like therapeutic agents* (invited address). Presentation at: **FDA Center for Drug Evaluation and Research (CDER) Visiting Professor Lecture Series**, in Brookside Gardens, Wheaton, MD.

- Batman, A., Beardsley, P. M., Reith, M. A. and Dutta, A. K., (2008). *Investigating DAT uptake inhibitors as potential replacement therapies for cocaine*. Presentation at: **Experimental Biology 2008**, in San Diego, CA.
- Beardsley, P. M., (2006). *Preclinical Abuse Liability: Abuse Deterrent Products (invited panelist)*. **Tufts Health Care Institute's Program on Opioid Risk Management**, in Boston, MA.
- Beardsley, P. M., (2006). *Nonclinical Abuse Liability Assessment & U.S. Regulatory Process (invited address)*. Presentation at: **GlaxoSmithKline, Inc.**, in Research Triangle Park, NC.
- Beardsley, P. M., (2006). *Drug self-administration & physical dependence testing (invited workshop facilitator)*. Presentation at: **Safety Pharmacology Society**, in San Diego, CA.
- Beardsley, P. M., (2006). *Developing a Cocaine Substitute with Reduced Toxicity and Reduced Abuse Liability (invited address)*. Presentation at: **Philip Morris USA**, in Richmond, VA.
- Beardsley, P. M. and Shelton, K. L., (2006). *Some Determinants of Reinstating Extinguished Methamphetamine Performance in Rats*. Presentation at: **International Study Group Investigating Drugs as Reinforcers**, in Sottsdale, AZ.
- Beardsley, P. M. and Newman, J. L., (2006). *Effects of NMDA and NMDA antagonists on cocaine-associated conditioned reinforcer-induced reinstatement*. Presentation at: **College on Problems of Drug Dependence**, in Scottsdale, AZ.
- Beardsley, P. M., (2006). *Results with L-001242178 in Nonclinical Abuse Liability Procedures*. Presentation at: **Merck & Co., Inc.**, in West Point, PA.
- Newman, J. L. and Beardsley, P. M., (2005). *Effects of NMDA antagonists on primary and secondary reinforcing properties of cocaine*. Presentation at: **The College on Problems of Drug Dependence, Inc.**, in Orlando, FL.
- Beardsley, P. M. and Cook, C., (2005). *Establishment of GHB discrimination in mice: Tests with the GHB precursors, 1,4 BD and GBL, the putative GHB receptor antagonist, NCS382, and an euthanasia agent, embutramide (invited address)*. Presentation at: **Society for Stimulus Properties of Drugs**, in Washington, D.C.
- Beardsley, P. M., (2005). *JDTic, a potential treatment for cocaine relapse and depression (invited address)* Presentation at: **University of Virginia Health System, Department of Psychiatric Medicine**, in Charlottesville, VA.
- Beardsley, P. M., (2005). *A novel KOR antagonist, JDTic, selectively blocks stress-induced reinstatement of cocaine-directed behavior (invited symposium participant)*. Presentation at: **The College on Problems of Drug Dependence, Inc.**, in Orlando, FL.

- Beardsley, P. M., (2005). *Some preclinical approaches to developing medications for treating cocaine dependency (invited address)* Presentation at: **University of Virginia, Department of Psychiatric Medicine**, in Charlottesville, VA.
- Balster, R. L. and Beardsley, P. M., (2005). *Surrogate manipulations of drug kinetics and how they affect the abuse potential of drugs using non-human primates.* Presentation at: **Impact of Drug Formulation on Abuse Liability, Safety and Regulatory Decisions Conference**, in North Bethesda, MD.
- Vann, R. and Beardsley, P. M., (2004). *Duration of administration and dose determinants of nicotine behavioral dependence in rats.* Presentation at: **Virginia Academy of Science, 82nd Annual Meeting**, in Richmond, Virginia.
- Newman, J. L., Cook, C. D., Harris, L. S. and Beardsley, P. M., (2004). *Reinforcing and discriminative stimulus effects of heroin and oxycodone in rats.* Presentation at: **The College on Problems of Drug Dependence, Inc.**, in San Juan, Puerto Rico.
- Beardsley, P. M. and Shelton, K. L., (2004). *Cocaine-induced reinstatement following extinction with & without cocaine-associated stimuli.* Presentation at: **2004 Winter Conference on Animal Learning and Behavior**, in Winter Park, CO.
- Beardsley, P. M., Reith, M. A. and Dutta, A. K., (2004). *Reduction of cocaine self-administration in rhesus monkeys by a selective DAT piperidine analogue of GBR12935.* Presentation at: **The College on Problems of Drug Dependence, Inc.**, in San Juan, Puerto Rico.
- Beardsley, P. M. and Newman, J., (2004). *Strength of drug seeking is determined by drug dose and associated stimuli in cocaine self-administering rhesus monkeys.* Presentation at: **2004 Winter Conference on Animal Learning and Behavior**, in Winter Park, CO.
- Beardsley, P. M., (2004). *Abuse potential assessment and the US regulatory process (invited address).* Presentation at: **Merck & Co., Inc.**, in Rahway, NJ.
- Beardsley, P. M., (2004). *Abuse Potential Assessment and the US Regulatory Process: Focus on Cannabinoids (invited address).* Presentation at: **Organon Labs Ltd.**, in Glasgow, Scotland.
- Beardsley, P. M., (2004). *Stress-Induced Relapse of Cocaine-Directed Behavior (invited address).* Presentation at: **Alcohol and Drug Abuse Research Program, Washington State University**, in Pullman, WA, USA.
- Beardsley, P. M., (2004). *Patterning of Nicotine Exposure Regulates the Induction of Behavioral Dependence (invited address).* Presentation at: **Alcohol and Drug Abuse Research Program, Washington State University**, in Pullman, WA, USA.
- Beardsley, P. M., (2004). *KOR Antagonist, JDTic, Blocks Stress-Induced Relapse to Cocaine Seeking (invited address).* Presentation at: **Research Triangle Institute**, in Research Triangle Park, NC, USA.

- Beardsley, P. M., (2004). *Abuse potential assessment and related issues (invited workshop facilitator)*. Presentation at: **IQPC Safety Pharmacology**, in Philadelphia, PA.
- Beardsley, P. M., (2003). *Results with oxycodone in non-clinical tests used to assess abuse liability (invited address)*. Presentation at: **Purdue Pharma L.P.**, in Stamford, CT.
- Beardsley, P. M., (2003). *Some recent preclinical approaches to development of pharmacotherapies for cocaine dependence (invited address)*. Presentation at: **1st European Congress on Addictive Disorders**, in Alicante, Spain.
- Beardsley, P. M., (2003). *Patterning of nicotine exposure regulates the induction of behavioral dependence (invited address)*. Presentation at: **Winter 2003 Tobacco Etiology Research Network**, in Laguna Beach, CA.
- Beardsley, P. M., (2002). *GHB: Chemical, biochemical, and behavioral effects (invited discussant)*. Presentation at: **College of Problems of Drug Dependence**, in Montreal, Quebec, Canada.
- Beardsley, P. M., (2002). *Abuse liability evaluation & drug scheduling (invited presentation)*. Presentation at: **GlaxoSmithKline**, in Research Triangle Park, NC.
- Beardsley, P. M., (2002). *Drug and context as discriminative stimuli controlling drug seeking (invited address)*. Presentation at: **Winter Conference on Animal Learning and Behavior**, in Winter Park, CO.
- Willmore, C. B., Wiley, J., Beshpalov, A. Y. and Beardsley, P. M., (2001). *Performance in a fixed-consecutive-number task resolves differences in the cognitive effects of NMDA antagonists*. Presentation at: **Learning and Memory, Cold Springs Harbor Laboratory**, in Cold Springs Harbor, New York.
- Neznanova, O. N., Beshpalov, A. Y., Willmore, C. B. and Beardsley, P. M., (2001). *Decrement in food-maintained performance produced by site-selective NMDA receptor antagonists in rats*. Presentation at: **College on Problems of Drug Dependence, International Satellite Meeting**, in Scottsdale, Arizona.
- Coop, A., Aceto, M. D., Beardsley, P. M., France, C. P., Harris, L. S., Traynord, J. R., Winger, G., Woolverton, W. L. and Woods, J. H., (2001). *Biological evaluation of compounds for their physical dependence potential and abuse liability by the Drug Evaluation Committee (DEC)*. Presentation at: **College on Problems of Drug Dependence**, in Scottsdale, Arizona.
- Cook, C. D., Coop, A. and Beardsley, P. M., (2001). *Antagonism of the behavioral effects of gamma-hydroxybutyrate (GHB)*. Presentation at: **American Society of Pharmacology and Experimental Therapeutics**, in Orlando, Florida.
- Cook, C. D. and Beardsley, P. M., (2001). *Effects of dopamine D3/2 drugs on the discriminative stimulus effects of mu opioids in heroin trained rats*. Presentation at: **College of Problems of Drug Dependence**, in Scottsdale, Arizona.

- Dutta, A. K., Fei, X.-S., Beardsley, P. M. and Reith, M. A., (2000). *Novel N- and O-substituted 4-[[2-(diphenylmethoxy)-ethyl]-1-[(phenyl)methyl]piperidine analogs*. Presentation at: **College on Problems of Drug Dependence 2000 Meeting**, in San Juan, Puerto Rico.
- Beardsley, P. M., McCann, D. and Harris, L. S., (2000). *Effects of selegiline on heroin- and food-maintained performances in rhesus monkeys*. Presentation at: **College on Problems of Drug Dependence 2000 Meeting**, in San Juan, Puerto Rico.
- Zvartau, E. E., Bespalov, A. Y., Dravolina, O. A., Beardsley, P. M. and Balster, R. L., (1999). *Modulation of drug-conditioned responses by NMDA receptor antagonists*. Presentation at: **European College of Neuropsychopharmacology**, in
- Newman, J. and Beardsley, P. M., (1999). *Drug- and stress-induced heroin relapse in rats*. Presentation at: **The Sixteenth Annual Daniel T. Watts Research Symposium**, in Richmond, VA.
- Bespalov, A. Y., Dravolina, O. A., Beardsley, P. M., Balster, R. L. and Zvartau, E. E., (1999). *Modulation of cocaine-conditioned locomotion by site-selective NMDA receptor antagonists in rats*. Presentation at: **College on Problems of Drug Dependence 1999 Meeting**, in Acapulco, Mexico.
- Beardsley, P. M., Sokoloff, P., Balster, R. L. and Schwartz, J.-C., (1999). *The D3R partial agonist, DO897, reduces cocaine self-administration and stimulant discriminative effects but lacks stimulant activity*. Presentation at: **College on Problems of Drug Dependence**, in Acapulco, Mexico.
- Beardsley, P. M., (1999). *Is there a role for dopamine D3R agents in drug abuse? (invited address)*. Presentation at: **First International Meeting of the Behavioral Pharmacology Society and European Behavioural Pharmacology Society**, in Boston, MA.
- Willmore, C. B., Bespalov, A. Y. and Beardsley, P. M., (1998). *Fixed consecutive number performance is differently affected by NMDA ligands when stimulus control is manipulated*. Presentation at: **Society for Neuroscience**, in Los Angeles.
- Willmore, C. B., Bespalov, A. Y., Balster, R. L. and Beardsley, P. M., (1998). *Morphine-like stimulus effects of NMDA antagonists may be due to disruption of stimulus control*. Presentation at: **College on Problems of Drug Dependence Meeting**, in Scottsdale, Arizona.
- LaVecchia, K., Willmore, C. B., Beardsley, P. M. and Wiley, J. L., (1998). *Performance of a delayed nonmatch to position task is impaired by cholinergic and glutamatergic modulators*. Presentation at: **Virginia Academy of Sciences 1998 Meeting**, in
- Beardsley, P. M. and Harris, L. S., (1998). *Dopamine/opiate-active N-Butyrophenone prodine-like compounds produce heroin's stimulus effects*. Presentation at: **College on Problems of Drug Dependence 1998 Meeting**, in Scottsdale, AZ.
- Beardsley, P. M. and Balster, R. L., (1998). *The glycine antagonist, GV150526, does not have PCP-like discriminative stimulus effects and is not self-administered*.

Presentation at: **European Behavioral Pharmacology Society**, in Brno, Czech Republic.

- Willmore, C. B., Bespalov, A. Y., Harris, L. S. and Beardsley, P. M., (1997). *The differential effects of NMDA-active ligands on a behavioral operant task*. Presentation at: **Society for Neurosciences Meeting**, in New Orleans.
- Bespalov, A. Y., Balster, R. L. and Beardsley, P. M., (1997). *NMDA receptor antagonists attenuate tolerance to morphine's discriminative stimulus effects*. Presentation at: **The College on Problems of Drug Dependence 1997 Meeting**, in Nashville, TN.
- Beardsley, P. M. and Martin, B. R., (1997). *SR141716A precipitates suppression of operant response rates in THC chronically treated rats*. Presentation at: **College on Problems of Drug Dependence Meeting**, in Nashville, Tennessee.
- Bespalov, A. Y., Bowen, S. E., Tokarz, M. E., Beardsley, P. M. and Balster, R. L., (1996). *Pharmacological specificity of the ability of drugs to enhance the expression of morphine conditioned place preference in mice*. Presentation at: **College on Problems of Drug Dependence 1996 Meeting**, in San Juan, Puerto Rico.
- Beardsley, P. M. and Harris, L. S., (1996). *Dihydroetorphine (DHE) potently generates self-administration and heroin-like stimulus effects*. Presentation at: **Committee on Problems of Drug Dependence Meeting**, in San Juan, Puerto Rico.
- Bespalov, A. Y., Zvartau, E. E. and Beardsley, P. M., (1995). *Kynurenic acid attenuates the rewarding potential but fails to alter discriminative stimulus properties of opiates in rats*. Presentation at: **EUPHAR Congress**, in Milan, Italy.
- Bespalov, A. Y., Balster, R. L. and Beardsley, P. M., (1995). *Discriminative stimulus effects of NMDA receptor antagonists in morphine trained rats*. Presentation at: **International Workshop on Behavioural Pharmacology of Excitatory Amino Acids and Their Antagonists**, in Marseilles, France.
- Beardsley, P. M., Nicholson, K., Cook, C., Freaques, M., Harris, L. S., Balster, R. L. and Hua, L., (1995). *The reinforcing and discriminative stimulus effects of gamma-hydroxybutyric acid (GHB)*. Presentation at: **College on Problems of Drug Dependence Meeting**, in Scottsdale, Arizona.
- Beardsley, P. M. and Harris, L. S., (1995). *Intravenous heroin discrimination of intravenous heroin self-administration*. Presentation at: **International Study Group Investigating Drugs as Reinforcers Meeting**, in San Diego, California.
- Beardsley, P. M., Balster, R. L. and Carroll, F. I., (1994). *Evaluation of cocaine analogs more selective for dopamine uptake in rats and squirrel monkeys trained to discriminate cocaine from saline*. Presentation at: **College on Problems of Drug Dependence Meeting**, in Palm Beach, Florida.
- Tessari, M., Chiamulera, C., Valerio, E. and Beardsley, P. M., (1993). *Nicotine self-administration in the rat*. Presentation at: **International Meeting on Sensitization and Tolerance in Behavioural Pharmacology**, in Pistoia, Italy.

- Tacconi, S., Romanelli, L., Beardsley, P. M., Crespi, F., Reggiani, A. and Trist, D. G., (1993). *Effects of non-NMDA glutamate antagonists on cocaine-increased dopamine levels in the rat nucleus accumbens during in vivo microdialysis*. Presentation at: **Society for Neurosciences Meeting**, in Washington, D.C.
- Pitzele, B. S., Chandrakumar, N. S., Contreras, P. C., Allen, S. E., Clare, M., Savage, M. A., Hammond, D. L., Nevins, M. E., Nash, S. A., Beardsley, P. M., Ragan, D. and Lanthorn, T. H., (1992). *Tyrosyl amides as ligands at the phencyclidine receptor located on the NMDA-sensitive glutamate site*. Presentation at: **Society for Neurosciences Meeting**, in Anaheim, California.
- Hansen, D. W., Chandrakumar, N. S., Husa, R. K., Peterson, K. B., Tsymbalov, S., Williamson, L. N., Reichman, M. and Beardsley, P. M., (1992). *Tyrosyl diamides as potent mu and delta opioid receptor ligands*. Presentation at: **Society for Neurosciences Meeting**, in Anaheim, California.
- Bloss, J. L. and Beardsley, P. M., (1992). *Delta-opioid agonists, deltorphin II and DMT-DPDPE, produce physical dependence in mice*. Presentation at: **ASPET Society Meeting**, in Orlando, Florida.
- Beardsley, P. M., Lopez, O. T. and Bloss, J. L., (1992). *Naltrindole (NTI) is less effective than its benzofuran analog (NTB) in attenuating morphine's discriminative stimulus, Straub tail and dependence effects*. Presentation at: **Society for Neurosciences Meeting**, in Anaheim, California.
- Beardsley, P. M., (1991). *Serotonin 5-HT₃ antagonists: Potential neuropsychiatric applications from psychosis to drug abuse*. Presentation at: **TCM Technology Meeting**, in St. Louis, Missouri.
- Nevins, M. E. and Beardsley, P. M., (1990). *Characterization of the effect of antidepressants in the tail suspension test using CD-1 mice*. Presentation at: **Society for Neurosciences Meeting**, in St. Louis, Missouri.
- Beardsley, P. M. and Anthony, E. W., (1990). *The discriminative stimulus properties of the (+)-opiates do not generalize to those of morphine and have antitussive effects*. Presentation at: **Society for Neurosciences Meeting**, in St. Louis, Missouri.
- Beardsley, P. M., (1990). *Phencyclidine (PCP) discrimination of ethanol self-administration*. Presentation at: **Society of the Stimulus Properties of Drugs Meeting**, in St. Louis, Missouri.
- Nevins, M. E., Arnolde, S. M. and Beardsley, P. M., (1989). *Quantitative grip strength assessment as a means of evaluating muscle relaxation in mice*. Presentation at: **Society for Neurosciences Meeting**, in Phoenix, Arizona.
- Knisely, J. S., Beardsley, P. M., Aceto, M. D., Balster, R. L. and Harris, L. S., (1989). *Assessment of the abuse potential of acetorphan, an enkephalinase inhibitor*. Presentation at: **American Psychological Association Meeting**, in New Orleans, Louisiana.

- Woolverton, W. L., Ator, N., Beardsley, P. M., Carroll, M. and Evans, H. L., (1988). *Dealing with the "psychological well-being" of primates*. Presentation at: **Behavioral Pharmacology Society Meeting**, in Savannah, Georgia.
- Beardsley, P. M., Salay, J. S. and Balster, R. L., (1988). *Intravenous self-administration of MK-801 by rhesus monkeys with cocaine and phencyclidine self-administration histories*. Presentation at: **ISGIDAR Satellite Session, Committee on Problems of Drug Dependence Meeting**, in Hyannis, Massachusetts.
- Beardsley, P. M., Salay, J. S. and Balster, R. L., (1988). *Effects of delay of reinforcement and dose on the self-administration of cocaine and procaine by rhesus monkeys*. Presentation at: **Behavioral Pharmacology Society Meeting**, in Savannah, Georgia.
- Beardsley, P. M. and Balster, R. L., (1988). *The effects of delay of reinforcement and dose on the self-administration of cocaine and procaine in rhesus monkeys*. Presentation at: **Chicago Pharmacology Chapter of ASPET**, in Chicago, Illinois.
- Balster, R. L., Willetts, J., Beardsley, P. M., Hayes, B. A. and Rice, A., (1988). *Excitatory amino acid neurotransmission and the behavioral pharmacology of phencyclidine-like drugs*. Presentation at: **Committee on Problems of Drug Dependence Meeting**, in Hyannis, Massachusetts.
- Beardsley, P. M., Kalant, H., Woodworth, I. and Stiglick, A., (1987). *Effects of ethanol self-administration and withdrawal in rats responding for food and water*. Presentation at: **June 1987 RSA / Committee on Problems of Drug Dependence Meeting**, in Philadelphia, Pennsylvania.
- Beardsley, P. M., Balster, R. L. and Harris, L. S., (1987). *Intravenous self-administration of antihistamines by rhesus monkeys*. Presentation at: **Joint ISGIDAR-SSPD Satellite Session, Committee on Problems of Drug Dependence Meeting**, in Philadelphia, Pennsylvania.
- Beardsley, P. M., Balster, R. L. and Harris, L. S., (1986). *Self-administration of methylenedioxymethamphetamine by rhesus monkeys*. Presentation at: **Joint ISGIDAR-SSPD Satellite Session, Committee on Problems of Drug Dependence Meeting**, in Lake Tahoe, Nevada.
- Beardsley, P. M., Balster, R. L. and Chapman, M., (1986). *Behavioral dependence upon PCP in the rat*. Presentation at: **Behavioral Pharmacology Society Meeting**, in Atlanta, Georgia.
- Beardsley, P. M. and Balster, R. L., (1985). *Separation of the response rate and discriminative stimulus properties of phencyclidine*. Presentation at: **Behavioral Pharmacology Society Meeting**, in Wilmington, Delaware.
- Beardsley, P. M., Balster, R. L. and Harris, L. S., (1984). *Behavioral dependence in rhesus monkeys following chronic THC administration*. Presentation at: **Committee on Problems of Drug Dependence Meeting**, in St. Louis, MO.

- Beardsley, P. M., Balster, R. L. and Harris, L. S., (1984). *Effects of delta-9-tetrahydrocannabinol on operant behavior of rhesus monkeys*. Presentation at: **August 1984 Satellite Symposium on Cannabis of the Ninth International Congress of Pharmacology**, in Oxford, England.
- Beardsley, P. M., Balster, R. L. and Harris, L. S., (1984). *Behavioral dependence of rhesus monkeys on intravenously-administered delta-9-tetrahydrocannabinol*. Presentation at: **Federation of American Societies for Experimental Biology**, in St. Louis, MO.
- Beardsley, P. M., (1981). *Oral self-administration of ethanol by rats*. Presentation at: **University of Minnesota Behavioral Pharmacology Retreat**, in Deerwood, Minnesota.
- Beardsley, P. M., (1981). *A precision drinking device for rats*. Presentation at: **Addiction Research Foundation of Ontario**, in Toronto, Ontario, Canada.
- Beardsley, P. M., (1981). *Studies of alcohol reinforcement*. Presentation at: **Addiction Research Foundation of Ontario**, in Toronto, Ontario, Canada.
- Beardsley, P. M., Lemaire, G. A. and Meisch, R. A., (1980). *Effects of duration between ethanol deliveries and concentration on ethanol-reinforced behavior in rats*. Presentation at: **Joint ISGIDAR-SSPD satellite session, Committee on Problems of Drug Dependence Meeting**, in Hyannis, Massachusetts.

083017